|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||291.69 - 297.51|
|52 Week Range||176.49 - 309.60|
|Beta (5Y Monthly)||1.04|
|PE Ratio (TTM)||10.06|
|Earnings Date||Oct. 25, 2021 - Oct. 29, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Mar. 29, 1994|
|1y Target Est||332.86|
According to LabCorp (LH), Vectra and the related IP and other assets from Myriad Genetics' autoimmune business complement its prior business activity.
Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.
BURLINGTON, N.C., September 13, 2021--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of select operating assets and intellectual property (IP) from Myriad Genetics’ autoimmune business unit, including the Vectra® rheumatoid arthritis (RA) assay.